{"filings":[{"id":500121,"accession_number":"0001628280-26-035967","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-05-18T20:30:52+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem announces $20M stock repurchase program beginning July 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $20M stock repurchase program, starting July 1, 2026 through June 30, 2028.","Program supersedes existing authorization expiring June 30, 2026; under prior, ~1.6M shares repurchased for ~$11.9M as of March 31, 2026.","Repurchases may be made via open market, private transactions, or other means under Rule 10b-18.","CEO Lachance cites confidence in disciplined execution, profitable growth, and strong balance sheet.","Company prioritizes strategic investments but will opportunistically repurchase when valuations are attractive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78561,"accession_number":"0001628280-26-034839","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-05-14T13:04:06+00:00","items":["5.02","9.01"],"status":"ready","headline":"InfuSystem Holdings elects Beverly Huss as Chairman of the Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Beverly Huss appointed Chairman effective May 11, 2026 following annual meeting.","No arrangements or understandings with any person regarding her appointment.","No family relationships with directors or executive officers, and no material interest in reportable transactions.","No other director or officer changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42801,"accession_number":"0001628280-26-034217","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-05-12T21:21:12+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"InfuSystem stockholders approve equity plan amendment raising share reserve to 7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Third Amendment to 2021 Equity Plan, increasing authorized shares to 7,000,000, enabling further equity awards.","All seven Board nominees elected: Drs. Eichenbaum/Sviokla, Messrs. Gendron/Hundzinski/Shuda, Mses. Huss/Lachance.","Non-binding say-on-pay advisory vote passed: 11,915,842 for, 1,071,346 against, 83,491 abstain.","Ratification of Grant Thornton LLP as independent auditor for FY 2026 passed: 16,604,725 for, 613 against, 193,626 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92307,"accession_number":"0001628280-26-031649","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Q1 net rev $33.7M (-3% YoY); net income $1.0M vs prior loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Patient Services rev $22.1M (+6% YoY); wound care revenue more than doubled to $2.1M.","Device Solutions rev $11.6M (-17% YoY) due to GE Healthcare contract restructure.","Gross margin expanded to 58.4% from 55.2%; adjusted EBITDA $6.4M (18.9% margin).","Full-year 2026 guidance reaffirmed: pro-forma net rev growth 6-8%, adj EBITDA margin mid-to-low 20%.","Repurchased $856k of common stock; liquidity $57.1M; new ERP went live March 1, 2026."],"consensus_eps_estimate":0.0341,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":33684000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92306,"accession_number":"0001628280-26-028564","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q1 2026 results on May 7, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings release before market open on Thursday, May 7, 2026.","Conference call at 9:00 a.m. ET same day; dial-in (833) 366-1127 or (412) 902-6773.","Webcast available at https://ir.infusystem.com/; replay through May 14, 2026 (code 1097864)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103069,"accession_number":"0001628280-26-019649","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"InfuSystem dismisses Deloitte, appoints Grant Thornton as auditor for FY 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee dismissed Deloitte & Touche LLP on March 13, 2026 after competitive selection process.","Grant Thornton LLP appointed as independent auditor for fiscal year ending December 31, 2026.","No disagreements with Deloitte on accounting principles or audit scope during 2024-2025 and interim period.","Deloitte's audit reports for 2024 and 2025 contained no adverse opinion or qualification.","Deloitte provided letter dated March 19, 2026 agreeing with disclosures; no reportable events occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103068,"accession_number":"0001628280-26-018216","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to present at 38th Annual ROTH Conference on March 23, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Carrie Lachance and CFO Barry Steele will attend the ROTH Conference on March 23, 2026.","Conference held at The Ritz-Carlton Laguna Niguel, Dana Point, CA.","Management to host in-person one-on-one meetings throughout the day.","Investors can arrange meetings via ROTH Capital representative or online registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103067,"accession_number":"0001628280-26-012895","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.","2025 adjusted EBITDA of $31.5M (21.9% margin) vs $25.3M (18.8%) in 2024; cash flow from operations $24.4M.","Patient Services revenue $86.5M (60% of total), Device Solutions $56.9M (40%); gross margin 56.0%.","Share repurchase program: $11.0M bought back through Dec 31, 2025; $20M authorization expires June 2026.","Net leverage 0.52x, debt/equity 0.75x, total available liquidity $58.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103066,"accession_number":"0001628280-26-010859","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Reports Seventh Consecutive Year of Record Net Revenues of $143.4M, Net Income Up 183%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year net revenues $143.4 million, a 6% increase over prior year.","Net income for 2025 was $6.6 million, up 183% from prior year.","Adjusted EBITDA (non-GAAP) reached $31.5 million, up 24%.","Fourth quarter net revenues $36.2 million, up 7%; net income $2.0 million, up 118%.","Company projects FY2026 pro-forma revenue growth of 6% to 8% after $7.1M contract restructuring."],"consensus_eps_estimate":0.0738,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":143436000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103065,"accession_number":"0001628280-26-008296","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q4/FY2025 preliminary results on Feb 24, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will issue preliminary Q4 and full-year 2025 results before market open on Tuesday, February 24, 2026.","Conference call scheduled for 9:00 a.m. ET on February 24, 2026; dial-in (833) 366-1127 or (412) 902-6773.","Webcast and replay available on the Investors section of InfuSystem's website.","No financial results or guidance disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119301,"accession_number":"0001628280-25-056364","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem gets CMS separate payment for two pain pumps under NOPAIN Act starting Jan 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS added CADD-Solis (ICU Medical) and Sapphire (Eitan Medical) pumps to qualifying list for separate payment.","Separate payment up to $1,997.16; program effective Jan 1, 2026 through Dec 31, 2027.","CEO says rule change could boost Pain Management volume growth but outlook tempered until adoption understood.","Pumps received brand-specific HCPCS codes C9815 and C9811 for HOPD and ASC claim submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119300,"accession_number":"0001628280-25-052068","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem TTM revenue $141.1M, AEBITDA $30.2M; guides 6-8% FY2025 growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTM revenue through Sep 30, 2025: $141.1M; estimated 2025 revenue grows 6-8% over 2024's $134.9M.","Adjusted EBITDA TTM $30.2M (21.4% margin); estimated 2025 AEBITDA margin >20% of revenue.","Patient Services net revenue TTM $85.4M; Device Solutions $55.7M; gross margin 55.4%.","Stock repurchases of $9.7M under $20M program through Sep 30, 2025; program expires Jun 30, 2026.","ERP upgrade investment estimated $2.6M in 2025 ($3.3M cumulative); expected completion Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119299,"accession_number":"0001628280-25-051090","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem CEO and CFO to attend Craig-Hallum conference Nov 18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carrie Lachance (CEO) and Barry Steele (CFO) will participate in the 16th Annual Craig-Hallum Alpha Select Conference.","Conference is on November 18, 2025, at the Sheraton New York Times Square Hotel in NYC.","Management will host in-person one-on-one meetings throughout the day.","Interested investors should contact their Craig-Hallum conference representative or Lytham Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119298,"accession_number":"0001628280-25-048516","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Q3 2025 revenue $36.5M (+3% YoY), net income $2.3M (+25%), reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $36.5M (record), up 3% vs. $35.3M a year ago; Patient Services up 8%, Device Solutions down 3%.","Net income $2.3M ($0.11 diluted EPS) vs. $1.8M ($0.08) prior year, a 25% increase.","Adjusted EBITDA $8.3M (+6%), margin 22.8% (up 0.5pp); YTD operating cash flow $17.3M (+38%).","Wound care revenue surged 115% YoY ($1.0M); new contract with large hospital system and payer extension secured.","Reaffirms full-year 2025 guidance: net revenue growth 6-8%, Adjusted EBITDA margin 20%+."],"consensus_eps_estimate":0.0816,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":107206000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119297,"accession_number":"0001628280-25-046748","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem announces Q3 2025 earnings release and call on Nov. 4","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Q3 2025 financial results to be issued before market open on November 4, 2025.","Conference call at 9:00 a.m. ET same day; dial-in (833) 366-1127 or (412) 902-6773.","Live webcast available on company's investor relations site; replay available for 90 days.","No financial results or guidance provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119296,"accession_number":"0001628280-25-044357","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem updates TTM revenue to ~$140M, adj EBITDA ~$30M; net leverage 0.86x","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTM 6/30/25 net revenue ~$140M, up from $134.9M in FY2024; adjusted EBITDA ~$30M vs. $25.3M.","Net leverage 0.86x, debt/equity 0.85x, total available liquidity $49.1M.","Share repurchase: $7.6M bought under $20M program through June 30, 2025.","Patient Services gross margin 64.5% TTM; Device Solutions gross margin 39.6% TTM.","Management estimates FY2025 revenue growth 6-8% and adjusted EBITDA margin >20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135875,"accession_number":"0001628280-25-042799","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem CEO and CFO to present at ROTH Healthcare Conference on Oct 9","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carrie Lachance (CEO) and Barry Steele (CFO) present at 4th Annual ROTH Healthcare Opportunities Conference.","Conference held October 9, 2025 at Metropolitan Club in New York City.","Management will host virtual one-on-one meetings throughout the day.","Investors can arrange meetings via conference representative or Lytham Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135874,"accession_number":"0001628280-25-037582","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Q2 net revenue $36M (+7% YoY); net income up 262% to $2.6M; raises FY25 EBITDA margin guidance to 20%+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $36.0M (+7% YoY); Patient Services $21.5M (+6%), Device Solutions $14.5M (+8%).","Net income $2.6M ($0.12 diluted EPS) vs $0.7M ($0.03) prior year; Adjusted EBITDA $8.0M (+32%).","Gross margin expanded 5.7 pts to 55.2%; YTD operating cash flow $8.8M (up 227%).","FY25 revenue growth guidance lowered to 6-8% (from 8-10%), but Adjusted EBITDA margin raised to 20%+ (from 18.8%+).","Repurchased $3.5M of stock in Q2; acquired a small company for $1.4M to improve Advanced Wound Care processing."],"consensus_eps_estimate":0.0367,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":70718000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135873,"accession_number":"0001628280-25-036435","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q2 2025 results on Aug 5 before market open","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Q2 2025 earnings release scheduled for August 5, 2025 before market open.","Conference call at 9:00 a.m. ET on August 5; dial-in (833) 366-1127 or (412) 902-6773.","Webcast and replay available on InfuSystem IR site; replay through August 12 via code 5094847."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135872,"accession_number":"0001628280-25-035245","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"InfuSystem extends credit agreement maturity to July 15, 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment to Credit Agreement with JPMorgan as agent extends maturity to July 15, 2030.","Borrowers: InfuSystem Holdings, Inc. and InfuSystem, Inc.; lenders include JPMorgan, Wells Fargo, Comerica, Northwest Bank.","Amendment updates interest rate benchmarks (SOFR-based), financial covenants, and other terms.","Borrowers paid all fees due; conditions precedent satisfied for effectiveness on July 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152860,"accession_number":"0001628280-25-029052","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["3.03","5.03","5.02","9.01"],"status":"ready","headline":"InfuSystem signs new CEO employment agreement with Carrie Lachance; $500K base, 200K PSUs, 128K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $500,000; annual bonus up to 100% of base based on performance targets set by Compensation Committee.","Grant of 200,000 performance-based restricted stock units (PSUs) with vesting tied to stock price targets through 2028.","Grant of 128,000 stock options vesting 25% per year over 4 years.","Severance: 12 months salary on involuntary termination; 18 months on change-of-control termination.","CEO transition from President/COO to President/CEO effective May 19, 2025; agreement dated May 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152859,"accession_number":"0001628280-25-026831","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"InfuSystem shareholders approve equity plan increase to 6M shares; Board elects Hundzinski Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved Second Amendment to 2021 Equity Plan, increasing reserved shares to 6,000,000 from prior limit.","Board elected Ronald Hundzinski as Chairman and disbanded the Executive Chairman role.","All seven director nominees elected; advisory say-on-pay proposal passed with 85% of votes cast.","Stockholders approved amendments to Certificate of Incorporation: exclusive forum provision and officer exculpation.","Ratification of Deloitte & Touche as independent auditor for FY 2025 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152858,"accession_number":"0001628280-25-024273","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem provides FY2025 outlook: 8-10% revenue growth, high-teens AEBITDA margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTM revenue to March 31, 2025: $137.6M; TTM adj. EBITDA $27.8M (leverage 0.98x).","Q1 2025 adj. EBITDA $6.3M (incl. $1.0M CEO severance) vs. $3.9M in Q1 2024.","FY2025 guidance: revenue growth 8-10% and adj. EBITDA margin in high teens % of revenue.","ERP upgrade: $0.7M spent in 2024, est. $2.5M in 2025; completion expected Q1 2026.","Share repurchases: $4.1M bought YTD under renewed $20M program (expires June 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152857,"accession_number":"0001628280-25-023417","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Q1 revenue $34.7M (+9% YoY); Adj. EBITDA $6.3M (+64%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $34.7M (+9% YoY); net loss narrowed to $0.3M ($0.01 loss per share) from $1.1M.","Adjusted EBITDA $6.3M (+64% YoY); margin expanded 6.2pp to 18.2%.","Patient Services revenue up 12% to $20.8M; Device Solutions up 4% to $13.9M.","FY 2025 guidance reaffirmed: revenue growth 8-10%; Adj. EBITDA margin high teens.","CEO transition: Richard DiIorio out; Carrie Lachance (COO) incoming; $1.0M severance accrued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":34716000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152856,"accession_number":"0001628280-25-021307","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q1 2025 results on May 8; conference call same day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["InfuSystem (INFU) will issue Q1 2025 financial results on May 8, 2025 before market open.","Conference call scheduled for 9:00 a.m. ET on May 8; dial-in (833) 366-1127 or (412) 902-6773.","Webcast and replay available at ir.infusystem.com; phone replay access code 6704669 through May 15.","No financial data released yet; press release only announces date and call logistics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152855,"accession_number":"0001628280-25-015754","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InfuSystem CEO Richard DiIorio to step down; Carrie Lachance named new CEO effective May 19, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard DiIorio to step down as CEO effective May 19, 2025; separation not due to any disagreement with the Company.","Carrie Lachance, President & COO, appointed CEO effective May 19, 2025; she joined InfuSystem in 2010 and has held multiple roles.","Scott Shuda appointed Executive Chairman of the Board.","Company reaffirms FY2025 guidance: net revenue growth 8–10% and Adjusted EBITDA margin exceeding 18.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171664,"accession_number":"0001628280-25-009610","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem reports record 2024 revenue of $134.9M, +7% YoY; Adj EBITDA +13% to $25.3M; guides 2025 revenue growth 8-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $33.8M (+7% YoY); net income $0.9M ($0.04 EPS) vs $0.1M prior year.","Full year adj EBITDA $25.3M (+13%); operating cash flow $20.5M (+82%).","Patient Services rev $80.4M (+5%), Device Solutions $54.5M (+11%) for full year.","2025 guidance: revenue growth 8-10%, adj EBITDA margin above 18.8%.","Repurchased $1.2M in 2024 and ~$2.4M in Q1 2025; net debt down $5.5M to $23.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171663,"accession_number":"0001628280-25-007550","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to announce Q4 and FY2024 earnings on March 4, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Preliminary Q4 and full year 2024 results to be issued before market open on March 4, 2025.","Conference call at 9:00 a.m. ET on March 4, 2025; dial-in (833) 366-1127 or (412) 902-6773.","Webcast available via Company IR site at https://ir.infusystem.com/.","Replay available by phone through March 11, 2025 at (877) 344-7529, access code 9301008."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188660,"accession_number":"0001628280-24-049931","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).","Adjusted EBITDA estimated at $26.5M for FY2024, margin ~19.7% (high teens % of revenue).","Net leverage ratio 1.15x; debt/equity 0.90x; $20M stock repurchase program available.","Capital allocation prioritized: organic growth, debt reduction (target leverage 1.5x-2.0x), and opportunistic buybacks.","Patient Services gross margin improved to 66.0% TTM; Device Solutions gross margin 31.3% TTM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188659,"accession_number":"0001628280-24-048920","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to present at Sidoti Small Cap Virtual Conference on Dec 4, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Richard DiIorio, CFO Barry Steele, and President/COO Carrie Lachance will present.","Presentation scheduled for 10:00 a.m. ET on Wednesday, December 4, 2024.","Webcast available on Company's IR website; replay will be posted afterward.","Management will host virtual one-on-one meetings; investors contact Lytham Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188658,"accession_number":"0001628280-24-048184","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InfuSystem appoints Ron Hundzinski as independent director effective Nov 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Hundzinski fills the new seat.","Hundzinski will serve on the Audit Committee and is an audit committee financial expert.","He retired in 2023 after CFO roles at TI Fluid Systems, Tenneco, and BorgWarner.","Hundzinski also chairs Gentherm's board; brings accounting/finance depth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188657,"accession_number":"0001628280-24-045952","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).","Net income $1.8M (+162%), diluted EPS $0.08; Adj EBITDA $7.9M (+27%), margin 22.3%.","Operating cash flow YTD $12.5M (+91%); liquidity $46.9M as of Sept 30, 2024.","Reaffirms FY2024 guidance: high-single-digit revenue growth, Adj EBITDA margin high-teens.","New partnerships: Smith+Nephew for NPWT and exclusive Chemo Mouthpiece deal with Sanara MedTech."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":101013000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188656,"accession_number":"0001628280-24-044401","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q3 2024 results on Nov 7; conference call at 9 AM ET","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2024 financial results to be released before market open on Thursday, November 7, 2024.","Conference call to discuss results at 9:00 a.m. Eastern Time on November 7, 2024.","Dial-in numbers: (833) 366-1127 or (412) 902-6773; webcast available on company website.","Replay available via (877) 344-7529 or (412) 317-0088, access code 7261158, through Nov 14.","No preliminary financial data or guidance provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205121,"accession_number":"0001628280-24-041426","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to participate in Lytham Partners Fall 2024 Conference on Oct 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Richard DiIorio, President Carrie Lachance, CFO Barry Steele will attend conference on October 1, 2024.","Fireside chat with CEO at 3:30pm ET; webcast accessible via conference or company IR website.","Management available for one-on-one and group investor meetings; registration required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205120,"accession_number":"0001628280-24-040251","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).","Recent distribution agreements: Smith+Nephew RENASYS EDGE NPWT system; exclusive U.S. ChemoMouthpiece with Sanara MedTech.","Patient Services revenue $77.3M (TTM 6/30/24); Device Solutions $52.1M; gross margins 64.9% and 29.4%.","Net leverage 1.53x; $40.5M total liquidity; $20M share repurchase program authorized.","Five consecutive years of record revenue; 12% revenue CAGR 2019-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205119,"accession_number":"0001628280-24-040073","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem and Sanara secure exclusive US distribution deal for ChemoMouthpiece oral cryotherapy device","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.","Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece; SI Technologies has a purchase option on the US business through January 2029.","Product targets 500,000–1,000,000 annual oral mucositis patients; estimated US market exceeds $600 million.","InfuSystem's existing oncology sales force will market the device to ~3,000 cancer centers.","AMA issued a new CPT code (effective July 2024) for reimbursement of the oral cryotherapy procedure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205118,"accession_number":"0001628280-24-039215","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to present at Lake Street BIG8 Conference on Sept 12, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Richard DiIorio and CFO Barry Steele will attend the conference.","Management will hold one-on-one and group meetings with investors.","Conference is at The Yale Club in New York City.","Contact Lytham Partners or Lake Street for meeting requests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205117,"accession_number":"0001628280-24-035842","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem Q2 net revenue $33.7M (record), net income $0.7M (+65% YoY); reaffirms FY24 high-single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $33.7M (+6% YoY); net income $0.7M ($0.03 diluted EPS) vs $0.4M ($0.02) prior year.","Patient Services rev $20.2M (+5%), Device Solutions $13.5M (+8%); overall gross margin 49.5% (down 0.4%).","Adjusted EBITDA $6.1M (18.0% margin), up 5.4% YoY; operating cash flow $2.7M (+17%).","Device Solutions gross margin fell 8.1% to 24.0% due to $0.6M error correction and unfavorable mix.","Reaffirmed FY24 guidance: high-single-digit revenue growth, Adjusted EBITDA margin in high-teens."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":65693000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205116,"accession_number":"0001628280-24-034940","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem signs 3-year distribution pact with Smith+Nephew for NPWT system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three-year agreement to distribute Smith+Nephew's RENASYS EDGE negative pressure wound therapy system.","InfuSystem will leverage its network of 800+ in-network health insurers covering 96% of the U.S. population.","First shipment of NPWT systems has already occurred under the partnership.","CEO cites ability to wrap high-value services around the product to drive new revenue opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205115,"accession_number":"0001628280-24-034443","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem announces Q2 2024 earnings release and conference call for August 8, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Q2 2024 financial results to be released before market open on August 8, 2024.","Conference call at 9:00 a.m. ET on August 8, 2024; dial-in (833) 366-1127 or (412) 902-6773.","Webcast and replay available on InfuSystem's investor relations website for 90 days.","No preliminary results or guidance provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222009,"accession_number":"0001628280-24-027849","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.","Q1 2024 revenue $32.0M; adjusted EBITDA $3.9M (vs. $4.2M in Q1 2023).","Guidance: 2024 revenue ~$134.2M (high single-digit growth); adjusted EBITDA ~$26.5M (margin 19.7%).","Patient Services gross margin stable at ~63%; Device Solutions gross margin declined to 31.5% (TTM).","Capital allocation: $20M share repurchase program; net leverage 1.32x; NOLs $26.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222008,"accession_number":"0001628280-24-026577","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to present at Sidoti Small Cap Conference on June 12, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Richard DiIorio, CFO Barry Steele, and President Carrie Lachance will present.","Presentation at 8:30 a.m. ET on Wednesday, June 12, 2024, at virtual Sidoti conference.","Webcast available on company's IR website at https://ir.infusystem.com.","Management will hold virtual one-on-one meetings throughout the day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222007,"accession_number":"0001628280-24-024370","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem authorizes $20M stock buyback through June 2026, replacing expiring program","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved repurchase of up to $20M of common stock through June 30, 2026.","Program supersedes prior authorization that expired June 30, 2024; prior program repurchased ~550k shares for ~$6.2M.","CEO cites confidence in solid operations, balance sheet strength, and 2024 outlook.","Repurchases may be made via open market or private transactions under Rule 10b-18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222006,"accession_number":"0001628280-24-024122","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"InfuSystem stockholders elect all seven board nominees and approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: All seven board nominees elected, each receiving >9.8M for votes (broker non-votes 2.4M).","Proposal 2: Non-binding approval of NEO compensation: 8,447,458 for, 7,411,428 against, 6,763 abstain.","Proposal 3: Ratification of Deloitte & Touche as auditor for FY2024: 16,164,598 for, 1,930,216 against, 180,229 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222005,"accession_number":"0001628280-24-021926","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem reports Q1 revenue up 5% to $32.0M; net loss widens, reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $32.0M (+5% YoY); record quarterly revenue.","Gross margin improved to 51.5% from 49.2%; gross profit +10%.","Net loss widened to $1.1M ($0.05/share) from $0.3M ($0.02) a year ago.","Adjusted EBITDA fell 9% to $3.9M, with margin of 12.1% vs 13.9%.","FY 2024 guidance reaffirmed: high-single-digit revenue growth, high-teens EBITDA margin."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":31995000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222004,"accession_number":"0001628280-24-020029","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q1 2024 earnings on May 9, 2024 before market open","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["First quarter 2024 financial results to be released on Thursday, May 9, 2024 before market opens.","Conference call scheduled for May 9 at 9:00 a.m. ET; dial-in: (800) 285-6670 or (713) 481-1320.","Live webcast and replay available at https://ir.infusystem.com/ for 90 days.","Replay access code 159874 available through May 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222003,"accession_number":"0001628280-24-014470","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"InfuSystem warned by NYSE American for failing to file 2023 10-K on time","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American non-compliance notice due to failure to file 2023 Annual Report by April 1, 2024.","Has up to six months initial cure period; may get additional six months at exchange's discretion.","Late filing stems from potential errors in expense classification (G&A vs. cost of sales) and ASC 842 lease accounting.","No assurance cure will be successful; failure could lead to suspension and delisting.","Company intends to regain compliance; stock ticker INFU on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241529,"accession_number":"0001628280-24-011061","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InfuSystem reports FY2023 record revenue $125.8M, +14%; EPS $0.04; guides FY2024 high-single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).","Q4 net revenue $31.8M (+10%); net income $0.1M ($0.00 diluted EPS) vs $0.1M ($0.01) prior year.","Adjusted EBITDA $22.4M (+8%); operating income $4.1M (+147%); net income $0.9M vs $0.0M prior year.","FY2024 guidance: high-single-digit revenue growth; Adjusted EBITDA margin in high-teens (above 17.8%).","Joint venture SI Wound Care (with Sanara MedTech) expected to generate meaningful revenue in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241528,"accession_number":"0001628280-24-010047","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Director Malhotra resigns from InfuSystem Board; company pays $625K under cooperation pact","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["R. Rimmy Malhotra resigned from the Board effective March 8, 2024; no disagreement cited.","Company pays $500K to Nicoya Capital and $125K to Malhotra as exit consideration for standstill, release, and voting commitments.","Malhotra and Nicoya agree to 3-year standstill: no stock acquisitions, proxy contests, or disparagement.","Malhotra approved the 2024 annual meeting director slate; Board also made stock ownership policy mandatory for independent directors.","Parties release each other from pre-agreement claims except for enforceability or performance of the Cooperation Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241527,"accession_number":"0001628280-24-009780","cik":1337013,"company_name":"InfuSystem Holdings, Inc","ticker":"INFU","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InfuSystem to report Q4 and FY2023 preliminary results on March 14, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Preliminary Q4 and full-year 2023 financial results to be issued before market open on Thursday, March 14, 2024.","Conference call scheduled for 9:00 a.m. Eastern Time on March 14; dial-in (833) 366-1127 or (412) 902-6773.","Webcast and replay available at https://ir.infusystem.com/ for 90 days; replay access code 2665790."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":187992568.7318919,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-08T23:59:59+00:00|241527"}